Samanta Cimitan will join Lonza as Chief Commercial Officer (CCO), Senior Vice President and a member of the Extended Executive Committee on 1 January 2027. In the newly created role, she will lead Strategic Enterprise Account Management, Global Marketing and Commercial Excellence. She´s been with Lonza before her CEO role at Celonic for the last three years.
Samanta Cimitan to (re)join Lonza from Celonic
AppointmentsSamanta Cimitan will join Lonza as Chief Commercial Officer (CCO), Senior Vice President and a member of the Extended Executive Committee on 1 January 2027. In the newly created role, she will lead Strategic Enterprise Account Management, Global Marketing and Commercial Excellence. She´s been with Lonza before her CEO role at Celonic for the last three years.
Apollo vaccine triggers broad rhinovirus immunity in Phase 1
Latest NewsUK biotech Apollo Therapeutics has reported early Phase 1 data showing that one dose of its experimental rhinovirus vaccine, APL-10456, induced immune responses recognizing all three rhinovirus species in healthy adults.
Immatics adds $150M ahead of anzu-cel readout
Latest NewsGerman biotech Immatics is raising $150 million (€128.6 million) through an underwritten offering to strengthen its balance sheet ahead of a pivotal readout for its lead cancer cell therapy, anzu-cel.
Revier launches with €6M to develop novel cardiometabolic approach
Latest NewsHeidelberg-based Revier Therapeutics has raised €6 million in seed financing to develop selective class IIa histone deacetylase (HDAC) inhibitors for cardiometabolic diseases.
Roche licenses Hanmi obesity drug for up to $2.3B
Latest NewsRoche’s Genentech unit has licensed global rights outside South Korea to HM17321, Hanmi Pharm’s Phase 1 obesity candidate. The deal gives Hanmi $190 million (€163 million) upfront and could be worth up to $2.3 billion (€2.0 billion), including development, regulatory and commercial milestones. Hanmi is also eligible for tiered royalties on future sales.
Hansa takes first step toward US Nasdaq listing
Latest NewsSweden’s Hansa Biopharma has confidentially filed paperwork with the U.S. Securities and Exchange Commission for a potential initial public offering of American depositary shares.
Proximity resolution: Swedish Pixelgen raises $15.5M to take cell architecture platform global
Latest NewsStockholm-based Pixelgen Technologies has raised $15.5 million in an oversubscribed Series B round to expand commercialization of its Proxiome platform. The Swedish company is targeting a gap in single-cell analysis: mapping how proteins are organized on the surface of individual cells, rather than simply measuring their abundance.
Moderna gives mRNA oncology a shot in the arm
Latest NewsA Phase III win for Moderna and Merck’s personalized mRNA cancer vaccine has reignited investor enthusiasm for mRNA — and put BioNTech back in the spotlight. But the data are more important than the stock rally: for the first time, a personalized mRNA cancer therapy has produced positive Phase III data in a major indication.
Another disappointment: AstraZeneca halts Phase III lung cancer trial for volrustomig
Latest NewsAstraZeneca has discontinued a pivotal Phase III trial of its dual checkpoint inhibitor volrustomig in metastatic non-small cell lung cancer (NSCLC), after an independent committee concluded that the study was unlikely to meet its primary endpoints. The setback comes as the company faces growing pressure to deliver new oncology products.
Merck-Bio-Techne: One step closer to fusion, deal clears German antitrust review
Latest NewsGermany’s Federal Cartel Office has cleared Merck KGaA’s planned acquisition of U.S. life sciences tools company Bio-Techne, removing one of the key regulatory hurdles to the €9.9 billion deal.